Abstract:In this work, sucrose acetate isobutyrate (SAIB) and polylactic co-glycolic acid (PLGA) were used alone or in combination as a matrix-former (MF) to prepare long-acting injectable rivastigmine (RV) in situ-forming microparticles (ISM). RV-ISM were prepared by the emulsification of an internal phase, containing the drug and the matrix former(s), into an external oily phase containing a stabilizer. The statistical design, Central Composite Design (CCD), was adopted as a quality by design (QbD) approach to optimize the formulation of RV-ISM systems. The fabricated RV-ISM systems was designed to minimize the initial burst drug release and maximize the sustainment of RV release from the ISM and ease of injection. The influence of critical formulation variables such as the matrix-former to drug (MF/D) ratio and SAIB to PLGA (S/P) ratio in the internal phase with respect to critical quality attributes (CQAs), such as the percentage drug release within the first day (Q1), the time required for 50% drug release (T50%) and the rate of injection, were studied using the CCD. The optimal RV-ISM system with the highest desirability value (0.74) was predicted to have an MF/D ratio of 11.7:1 (w/w) and an S/P ratio of 1.64:1 (w/w). The optimal RV-ISM system was assessed for its release profile, injectability, rheological properties, morphology, effect on cell viability, tolerance to γ-sterilization and in vivo performance in male albino rabbits. In vitro release studies revealed that the optimal RV-ISM system released 100% of its drug content throughout a release period of 30 days with only 15.5% drug release within the first day (Q1) and T50% of 13.09 days. Moreover, the optimal system showed a high injection rate of 1.012 mL/min, pseudoplastic flow, uniform spherical globules with homogenous particle size, minimal cytotoxicity and high tolerability to γ-sterilization. In vivo pharmacokinetic (PK) studies revealed that the rate of absorption of RV from the optimal RV-ISM system was controlled compared to a drug solution following either intramuscular (IM) or subcutaneous (SC) injection. Furthermore, the optimal RV-ISM was found to follow flip-flop PK with poor correlation between in vitro release and in vivo findings. These findings suggest that the optimal RV-ISM is a promising tool to achieve a sustained release therapy for RV; however, further investigation is still required to optimize the in vivo performance of RV-ISM.

In Vivo Evaluation of Risperidone-Saib in Situ System As a Sustained Release Delivery System in Rats.

An in situ-forming, solid lipid/PLGA hybrid implant for long-acting antipsychotics

Efficacy and Safety of Long-Acting Risperidone on Early Onset Schizophrenia in Adolescent Patients

Long-Acting Risperidone Dual Control System: Preparation, Characterization and Evaluation In Vitro and In Vivo

Study on pramipexole dihydrochloride sustained-release tablets

Formulation development and pharmacokinetic studies of long acting in situ depot injection of risperidone

Pharmacokinetics and Safety of a Novel Extended‐Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder

In Situ-Forming Microparticles for Controlled Release of Rivastigmine: In Vitro Optimization and In Vivo Evaluation

In vivo characterization of Perseris and compositionally equivalent formulations

Preparation and in vitro evaluation of risperidone loaded PLGA microspheres

Development of a novel 3-month drug releasing risperidone microspheres

Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM®

Mechanisms of long-acting injectable risperidone and its clinical application

Risperidone ISM®: review and update of its usefulness in all phases of schizophrenia

Risperidone-cyclodextrin complex reservoir combined with hydrogel-forming microneedle array patches for enhanced transdermal delivery

Physiologically-Based Pharmacokinetic Modeling and In Vitro-In Vivo Correlation of TV-46000 (Risperidone LAI): Prediction from Dog to Human

Preparation and characterization of silk fibroin hydrogel as injectable implants for sustained release of Risperidone

Physiologically Based Pharmacokinetic Modeling to Understand the Absorption of Risperidone Orodispersible Film.

Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique

Evaluating Non-Conventional Chitosan Sources for Controlled Release of Risperidone

[Unilateral hemothorax as sole clinical sign of kidney tumor].